Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, Geoffrey Y Ku, Yaelle Tuvy, Helen Won, Christopher J Fong, Nancy Bouvier, Gouri J Nanjangud, Joanne Soong, Efsevia Vakiani, Mark Schattner, David P Kelsen, Robert A Lefkowitz, Karen Brown, Mario E Lacouture, Marinela Capanu, Marissa Mattar, Besnik Qeriqi, Fabiola Cecchi, Yuan Tian, Todd Hembrough, Rebecca J Nagy, Richard B Lanman, Steven M Larson, Neeta Pandit-Taskar, Heiko Schöder, Christine A Iacobuzio-Donahue, David H Ilson, Wolfgang A Weber, Michael F Berger, Elisa de Stanchina, Barry S Taylor, Jason S Lewis, David B Solit, Jorge A Carrasquillo, Maurizio Scaltriti, Nikolaus Schultz, Yelena Y Janjigian
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an irreversible pan-HER kinase inhibitor, in trastuzumab-resistant EG cancer. We analyzed pretreatment tumor biopsies and, in select cases, performed comprehensive characterization of postmortem metastatic specimens following acquisition of drug resistance. Afatinib response was associated with coamplification of EGFR and ERBB2 ...
February 2019: Cancer Discovery